92 related articles for article (PubMed ID: 19186082)
1. Does RNA editing play a role in the development of urinary bladder cancer?
Zilberman DE; Safran M; Paz N; Amariglio N; Simon A; Fridman E; Kleinmann N; Ramon J; Rechavi G
Urol Oncol; 2011; 29(1):21-6. PubMed ID: 19186082
[TBL] [Abstract][Full Text] [Related]
2. ncRAN, a newly identified long noncoding RNA, enhances human bladder tumor growth, invasion, and survival.
Zhu Y; Yu M; Li Z; Kong C; Bi J; Li J; Gao Z; Li Z
Urology; 2011 Feb; 77(2):510.e1-5. PubMed ID: 21147498
[TBL] [Abstract][Full Text] [Related]
3. [Expression of apoptosis inhibitor gene Livin in bladder transitional cell carcinoma and clinical implication thereof].
Song T; Hong BF; Gao JP; Cai W; Wang CY
Zhonghua Yi Xue Za Zhi; 2007 Mar; 87(12):806-7. PubMed ID: 17565859
[TBL] [Abstract][Full Text] [Related]
4. Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma.
Tsui KH; Cheng AJ; Chang Pe; Pan TL; Yung BY
Urology; 2004 Oct; 64(4):839-44. PubMed ID: 15491744
[TBL] [Abstract][Full Text] [Related]
5. Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements.
Kunze E; Von Bonin F; Werner C; Wendt M; Schlott T
Int J Mol Med; 2006 Jan; 17(1):3-13. PubMed ID: 16328005
[TBL] [Abstract][Full Text] [Related]
6. p63 gene expression study and early bladder carcinogenesis.
Compérat E; Bièche I; Dargère D; Ferlicot S; Laurendeau I; Benoît G; Vieillefond A; Verret C; Vidaud M; Capron F; Bedossa P; Paradis V
Urology; 2007 Sep; 70(3):459-62. PubMed ID: 17905096
[TBL] [Abstract][Full Text] [Related]
7. Association of TSC1/hamartin, 14-3-3sigma, and p27 expression with tumor outcomes in patients with pTa/pT1 urothelial bladder carcinoma.
Mhawech-Fauceglia P; Alvarez V; Fischer G; Beck A; Herrmann FR
Am J Clin Pathol; 2008 Jun; 129(6):918-23. PubMed ID: 18480009
[TBL] [Abstract][Full Text] [Related]
8. Is abundant A-to-I RNA editing primate-specific?
Eisenberg E; Nemzer S; Kinar Y; Sorek R; Rechavi G; Levanon EY
Trends Genet; 2005 Feb; 21(2):77-81. PubMed ID: 15661352
[TBL] [Abstract][Full Text] [Related]
9. Gene expression in superficial bladder cancer in a tumor-model-system (RBT).
Knopf HJ; von Moorselaar RJ; Debruyne FM; Schalken JA
Investig Urol (Berl); 1994; 5():76-9. PubMed ID: 7719325
[No Abstract] [Full Text] [Related]
10. The value of DNA cytometry in transitional cell carcinoma of the urinary bladder.
Nenning H; Rassler J; Minh DH; Stolzenburg JU
Gen Diagn Pathol; 1997 Dec; 143(4):231-6. PubMed ID: 9489956
[TBL] [Abstract][Full Text] [Related]
11. Altered adenosine-to-inosine RNA editing in human cancer.
Paz N; Levanon EY; Amariglio N; Heimberger AB; Ram Z; Constantini S; Barbash ZS; Adamsky K; Safran M; Hirschberg A; Krupsky M; Ben-Dov I; Cazacu S; Mikkelsen T; Brodie C; Eisenberg E; Rechavi G
Genome Res; 2007 Nov; 17(11):1586-95. PubMed ID: 17908822
[TBL] [Abstract][Full Text] [Related]
12. Chromosomal high-polysomies predict tumour progression in T1 transitional cell carcinoma of the bladder.
Ribal MJ; Alcaraz A; Mengual L; Carrio A; Lopez-Guillermo A; Mallofré C; Palou J; Gelabert A; Villavicencio H
Eur Urol; 2004 May; 45(5):593-9. PubMed ID: 15082201
[TBL] [Abstract][Full Text] [Related]
13. Genetic and epigenetic aspects of bladder cancer.
Kim WJ; Quan C
J Cell Biochem; 2005 May; 95(1):24-33. PubMed ID: 15759278
[TBL] [Abstract][Full Text] [Related]
14. A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer.
Bowles L; Bialkowska-Hobrzanska H; Bukala B; Nott L; Razvi H
Can J Urol; 2004 Dec; 11(6):2438-44. PubMed ID: 15636669
[TBL] [Abstract][Full Text] [Related]
15. [Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder].
Song JW; DU LL; Zhao XW; Jing JX; Han CZ; Cui Y; Liu JW; Hao HL; Wang ZG; Mi ZG
Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):274-7. PubMed ID: 19615282
[TBL] [Abstract][Full Text] [Related]
16. Activation of RAS family genes in urothelial carcinoma.
Boulalas I; Zaravinos A; Karyotis I; Delakas D; Spandidos DA
J Urol; 2009 May; 181(5):2312-9. PubMed ID: 19303097
[TBL] [Abstract][Full Text] [Related]
17. Molecular markers for detection, surveillance and prognostication of bladder cancer.
Vrooman OP; Witjes JA
Int J Urol; 2009 Mar; 16(3):234-43. PubMed ID: 19298346
[TBL] [Abstract][Full Text] [Related]
18. [The study of p53 gene mutation in human bladder cancer].
Ding Q; Zhang Y; Sun X
Zhonghua Wai Ke Za Zhi; 1995 Nov; 33(11):684-6. PubMed ID: 8731915
[TBL] [Abstract][Full Text] [Related]
19. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status.
Maas S; Warskulat U; Steinhoff C; Mueller W; Grimm MO; Schulz WA; Seifert HH
Urology; 2004 Feb; 63(2):392-7. PubMed ID: 14972509
[TBL] [Abstract][Full Text] [Related]
20. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
